Metabolism of [123I]epidepride may affect brain dopamine D2 receptor imaging with single-photon emission tomography

Kim A. Bergström; Meixiang Yu; Jyrki T. Kuikka; Kari K. Åkerman; Jukka Hiltunen; Johannes Lehtonen; Christer Halldin; Jari Tiihonen

doi:10.1007/s002590050028

Metabolism of [¹²³I]epidepride may affect brain dopamine D₂ receptor imaging with single-photon emission tomography

Kim A. Bergström, Meixiang Yu, Jyrki T. Kuikka, Kari K. Åkerman, Jukka Hiltunen, Johannes Lehtonen, Christer Halldin, Jari Tiihonen

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Iodine-123 labelled epidepride is a novel radiopharmaceutical for the study of cerebral dopamine D₂ receptors using single-photon emission tomography (SPET). A lipophilic labelled metabolite of [¹²³I]epidepride which may enter the brain and hamper the quantitation of receptors has been observed in human plasma. In the present study, gradient high-performance liquid chromatography (HPLC) was used to investigate the plasma concentration of the lipophilic labelled metabolite and its correlation to SPET imaging of striatal dopamine D₂ receptors. A linear regression fit showed a negative correlation between the amount of the lipophilic labelled metabolite and the striatum to cerebellum ratio (n=16, R=-0.58, P<0.02), suggesting that plasma metabolite analysis is essential when imaging dopamine D₂ receptors with SPET using [¹²³I]epidepride.

Original language	English (US)
Pages (from-to)	206-208
Number of pages	3
Journal	European Journal of Nuclear Medicine
Volume	27
Issue number	2
DOIs	https://doi.org/10.1007/s002590050028
State	Published - 2000

Keywords

Epidepride
High- performance liquid chromatography
Metabolites
Single-photon emission tomography

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1007/s002590050028

Cite this

@article{a18c29a306a64596b7f840890b66dbb5,

title = "Metabolism of [123I]epidepride may affect brain dopamine D2 receptor imaging with single-photon emission tomography",

abstract = "Iodine-123 labelled epidepride is a novel radiopharmaceutical for the study of cerebral dopamine D2 receptors using single-photon emission tomography (SPET). A lipophilic labelled metabolite of [123I]epidepride which may enter the brain and hamper the quantitation of receptors has been observed in human plasma. In the present study, gradient high-performance liquid chromatography (HPLC) was used to investigate the plasma concentration of the lipophilic labelled metabolite and its correlation to SPET imaging of striatal dopamine D2 receptors. A linear regression fit showed a negative correlation between the amount of the lipophilic labelled metabolite and the striatum to cerebellum ratio (n=16, R=-0.58, P<0.02), suggesting that plasma metabolite analysis is essential when imaging dopamine D2 receptors with SPET using [123I]epidepride.",

keywords = "Epidepride, High- performance liquid chromatography, Metabolites, Single-photon emission tomography",

author = "Bergstr{\"o}m, {Kim A.} and Meixiang Yu and Kuikka, {Jyrki T.} and {\AA}kerman, {Kari K.} and Jukka Hiltunen and Johannes Lehtonen and Christer Halldin and Jari Tiihonen",

year = "2000",

doi = "10.1007/s002590050028",

language = "English (US)",

volume = "27",

pages = "206--208",

journal = "European Journal of Nuclear Medicine",

issn = "0340-6997",

publisher = "Springer Verlag",

number = "2",

}

TY - JOUR

T1 - Metabolism of [123I]epidepride may affect brain dopamine D2 receptor imaging with single-photon emission tomography

AU - Bergström, Kim A.

AU - Yu, Meixiang

AU - Kuikka, Jyrki T.

AU - Åkerman, Kari K.

AU - Hiltunen, Jukka

AU - Lehtonen, Johannes

AU - Halldin, Christer

AU - Tiihonen, Jari

PY - 2000

Y1 - 2000

N2 - Iodine-123 labelled epidepride is a novel radiopharmaceutical for the study of cerebral dopamine D2 receptors using single-photon emission tomography (SPET). A lipophilic labelled metabolite of [123I]epidepride which may enter the brain and hamper the quantitation of receptors has been observed in human plasma. In the present study, gradient high-performance liquid chromatography (HPLC) was used to investigate the plasma concentration of the lipophilic labelled metabolite and its correlation to SPET imaging of striatal dopamine D2 receptors. A linear regression fit showed a negative correlation between the amount of the lipophilic labelled metabolite and the striatum to cerebellum ratio (n=16, R=-0.58, P<0.02), suggesting that plasma metabolite analysis is essential when imaging dopamine D2 receptors with SPET using [123I]epidepride.

AB - Iodine-123 labelled epidepride is a novel radiopharmaceutical for the study of cerebral dopamine D2 receptors using single-photon emission tomography (SPET). A lipophilic labelled metabolite of [123I]epidepride which may enter the brain and hamper the quantitation of receptors has been observed in human plasma. In the present study, gradient high-performance liquid chromatography (HPLC) was used to investigate the plasma concentration of the lipophilic labelled metabolite and its correlation to SPET imaging of striatal dopamine D2 receptors. A linear regression fit showed a negative correlation between the amount of the lipophilic labelled metabolite and the striatum to cerebellum ratio (n=16, R=-0.58, P<0.02), suggesting that plasma metabolite analysis is essential when imaging dopamine D2 receptors with SPET using [123I]epidepride.

KW - Epidepride

KW - High- performance liquid chromatography

KW - Metabolites

KW - Single-photon emission tomography

UR - http://www.scopus.com/inward/record.url?scp=0033625021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033625021&partnerID=8YFLogxK

U2 - 10.1007/s002590050028

DO - 10.1007/s002590050028

M3 - Article

C2 - 10755727

AN - SCOPUS:0033625021

SN - 0340-6997

VL - 27

SP - 206

EP - 208

JO - European Journal of Nuclear Medicine

JF - European Journal of Nuclear Medicine

IS - 2

ER -